Coram W M, Olson R W, Beil M E, Cabot C F, Weiss G B
J Cardiovasc Pharmacol. 1987 May;9(5):611-21. doi: 10.1097/00005344-198705000-00016.
Metoprolol and other beta-adrenergic blocking drugs are known to exert cardioprotective effects that include significant reduction in occurrence of ventricular fibrillation (VF) following myocardial ischemia and infarction. To help determine the mechanism of these cardioprotective effects, this study evaluated the effect of equipotent beta-blocking doses of metoprolol and three other beta-blockers with differing ancillary properties on ventricular fibrillation threshold (VFT) in the normal canine heart. Metoprolol tartrate (1.0 mg/kg i.v.), atenolol (0.3 mg/kg i.v.), propranolol hydrochloride (0.3 mg/kg i.v.), pindolol (0.03 mg/kg i.v.), or saline control (0.9% NaCl solution; vehicle) was given, alone and in combination with lidocaine (L), to groups of six pentobarbital (32.5 mg/kg i.v.) anesthetized mongrel dogs after control VFT and control isoproterenol-induced (ISO) positive chronotropic effects had been determined. The D- (membrane stabilizing, non-beta blocking) and L- (beta blocking) isomers of propranolol also were administered to separate groups of six anesthetized dogs in a dose of 0.3 mg/kg i.v. Blood samples (venous) were taken before drug or vehicle administration, 10 min after drug/vehicle administration and at half-hour intervals thereafter during experimentation. ISO responses and VFT were determined 5 and 15 min, respectively, after drug/vehicle administration and at half-hour intervals for a total experimental period of 165 min. VF was induced with a train of pulses (5 s, 100 Hz, 3-ms duration, 250-omega resistance) applied by bipolar platinum electrodes to a paced heart (200 beats/min). Voltage (V) was increased every 60 sec (0.25-V increments between 0-3.5 V and 0.5-V increments greater than 3.5 V) until VF occurred. Metoprolol increased VFT significantly (p less than 0.05) and maximally (max delta V = 2.3 +/- 0.7 V) at 135 min postdrug when the ISO-induced increase in heart rate was inhibited (%I ISO) by less than 53%. Max delta V was not significantly increased following i.v. administration of atenolol (0.8 +/- 0.6 V), pindolol (0.1 +/- 0.1 V), or saline (0.1 +/- 0.1 V). Max delta V was 0.5 +/- 0.2 in the D-propranolol-treated group and 0.5 +/- 0.3 in the L-propranolol-treated group. These values did not differ from max delta V obtained in the propranolol-treated group (0.6 +/- 0.4 V). Changes in VFT for all groups were, over time, negatively correlated with %I ISO and were not dependent on membrane stabilizing effect (metoprolol, propranolol (D,DL), pindolol), intrinsic sympathomimetic activity (pindolol), or cardioselectivity (metoprolol, atenolol).(ABSTRACT TRUNCATED AT 400 WORDS)
已知美托洛尔和其他β-肾上腺素能阻滞剂具有心脏保护作用,包括显著降低心肌缺血和梗死后室颤(VF)的发生率。为了帮助确定这些心脏保护作用的机制,本研究评估了等效β-阻滞剂量的美托洛尔和其他三种具有不同辅助特性的β-阻滞剂对正常犬心脏室颤阈值(VFT)的影响。分别给六组戊巴比妥(32.5mg/kg静脉注射)麻醉的杂种犬静脉注射酒石酸美托洛尔(1.0mg/kg)、阿替洛尔(0.3mg/kg)、盐酸普萘洛尔(0.3mg/kg)、吲哚洛尔(0.03mg/kg)或生理盐水对照(0.9%氯化钠溶液;溶媒),单独给药以及与利多卡因(L)联合给药,给药前先测定对照VFT和对照异丙肾上腺素(ISO)诱导的正性变时作用。普萘洛尔的D-(膜稳定,非β阻滞)和L-(β阻滞)异构体也分别以0.3mg/kg静脉注射的剂量给予另外六组麻醉犬。在给药或给予溶媒前、给药后10分钟以及实验期间此后每隔半小时采集血样(静脉血)。分别在给药或给予溶媒后5分钟和15分钟以及此后每隔半小时测定ISO反应和VFT,总实验期为165分钟。通过双极铂电极向起搏心脏(200次/分钟)施加一串脉冲(5秒,100Hz,3毫秒持续时间,250欧姆电阻)诱导VF。每隔60秒增加电压(V)(0至 3.5V之间以0.25V递增,大于3.5V时以0.5V递增),直至发生VF。美托洛尔在给药后135分钟时显著增加VFT(p<0.05)且达到最大增幅(最大ΔV = 2.3±0.7V),此时ISO诱导的心率增加被抑制(%I ISO)小于53%。静脉注射阿替洛尔(0.8±0.6V)、吲哚洛尔(0.1±0.1V)或生理盐水(0.1±0.1V)后,最大ΔV未显著增加。D-普萘洛尔治疗组最大ΔV为0.5±0.2,L-普萘洛尔治疗组为0.5±0.3。这些值与普萘洛尔治疗组获得的最大ΔV(0.6±0.4V)无差异。所有组VFT的变化随时间与%I ISO呈负相关,且不依赖于膜稳定作用(美托洛尔、普萘洛尔(D、DL)、吲哚洛尔)、内在拟交感活性(吲哚洛尔)或心脏选择性(美托洛尔、阿替洛尔)。(摘要截短于400字)